AXSM — Axsome Therapeutics, Inc.

—
Nasdaq · Health Care · Pharmaceuticals · CIK 1579428 ·
Last close
$135.95
Market Cap
$7.15B
52W High
$260.19
52W Low
$123.00
ADV30
1,058,247
Next earnings
2026-11-02

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 259,691,000 241,887,000 -13,448,000 -12,877,000 826,773,000 313,859,000 721,339,000
Jun 2026 218,375,000 204,811,000 -51,142,000 -51,314,000 761,447,000 319,850,000 678,143,000
Mar 2026 191,203,000 176,478,000 -62,767,000 -64,542,000 713,607,000 305,106,000 659,020,000
Dec 2025 195,999,000 183,670,000 -36,025,000 -28,559,000 689,805,000 322,933,000 601,510,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-81,774,000
Investing CF
$-839,000
Financing CF
$71,200,000
CapEx
$-839,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-3.06
As of
2026-11-08

Balance + Analyst (yfinance extras)

Retained Earnings
$-1,434,694,000
Inventory
$42,579,000
Receivables
$343,114,000
ST Investments
—
EBIT TTM
$-151,028,000
Pretax Income TTM
$-156,646,000
Interest Exp TTM
$5,618,000
Analysts
21

Yahoo Snapshot (yfinance, live)

Total Revenue
$865,267,968
EBITDA
$-152,798,000
Free Cash Flow
$-24,377,250
Enterprise Value
$6,873,026,048
Total Cash
$313,859,008
Total Debt
$224,224,992
Shares Out
52,599,985
Trailing EPS
$-3.03
Book Value
$2.00
ROE
-175.6%
ROA
-13.7%
Div Yield
0.00%

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 638,496,000 -169,235,000 -183,174,000 689,805,000 601,510,000 88,295,000 -93,405,000
Dec 2024 385,693,000 -252,438,000 -287,216,000 568,498,000 511,483,000 57,015,000 -128,410,000
Dec 2023 270,600,000 -182,907,000 -239,238,000 588,236,000 397,259,000 190,977,000 -145,080,000
Dec 2022 50,037,000 -176,501,000 -187,134,000 331,476,000 221,920,000 109,556,000 -116,511,000

TTM Snapshot

Revenues TTM
$776,569,000
NetIncome TTM
$-191,644,000
OpCashFlow TTM
—
Assets (Latest)
$761,447,000
Forward EPS
$3.38

Max Pain — expiry 2027-01-15

max pain strike: $160.00 · spot: $134.00 · call oi: 4,832 · put oi: 5,148
Expected Move to 2027-01-15: ±$23.00 (17.16%) — implied range $111.00 – $157.00 · ATM straddle on $135.00 strike

Peers — same industry

TickerNameMarket CapLastDaily %
ABVX Abivax S.A. $7.16B $82.10 —
CYTK CYTOKINETICS INC $7.20B $51.65 —
AMRX Amneal Pharmaceuticals, Inc. $7.36B $21.12 —
ALKS Alkermes plc. $7.64B $45.45 —
CORT CORCEPT THERAPEUTICS INC $7.67B $70.07 —

News headlines (Yahoo Finance, 1h cache)

Axsome Therapeutics Sees AUVELITY Prescription Surge After Alzheimer’s Agitation Launch
2026-11-16 14:13 · Yahoo
Axsome Therapeutics vs. Moderna: Which Biotech Innovator Stock Is a Better Buy for 2027?
2026-11-14 16:32 · Yahoo
Nasdaq Sell-Off: 2 Stocks to Buy on the Dip and Hold for 5 Years
2026-11-11 23:26 · Yahoo
Axsome Therapeutics Tops $1 Billion Revenue Run Rate as AUVELITY Sales Surge
2026-11-10 04:14 · Yahoo
Is Axsome Therapeutics (AXSM) Fully Priced Given Its Sales Growth?
2026-11-07 05:21 · Yahoo
Axsome Therapeutics (AXSM) Stock Gets Fair Value Trim After Q3 Analyst Revisions
2026-11-06 11:13 · Yahoo
Axsome Therapeutics vs. BioNTech: Which Healthcare Stock Is a Better Buy for 2027?
2026-11-05 19:37 · Yahoo
Axsome: 3 Key Takeaways for Long-Term Investors
2026-11-04 14:29 · Yahoo
AXSM Stock Has Slumped Nearly 20% Over The Past Month, But BofA Sees Selloff As Overdone
2026-11-03 17:57 · Yahoo
Axsome Therapeutics Could Achieve Earnings in 2027 Amid Growing Auvelity Revenue, RBC Says
2026-11-03 16:28 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.